Neuroimaging in Parkinson's Disease

被引：56

作者：

Brooks D.J. ^{[1
]}

机构：

[1] Medical Research Council Clinical Sciences Center, Division of Neuroscience, Faculty of Medicine

来源：

NeuroRX | 2004年 / 1卷 / 2期

关键词：

dopamine; neuroprotection; Parkinson's disease; Positron emission tomography; progression; SPECT;

D O I：

10.1602/neurorx.1.2.243

中图分类号：

学科分类号：

摘要：

In this review, the potential role of positron emission tomography and single photon emission computed tomography as biological markers for diagnosing and following the progression of Parkinson's disease (PD) is discussed. Their value for assessing the efficacy of putative neuroprotective agents in PD and for revealing the pharmacological changes underlying the symptomatology and complications of this disorder is also considered. It is concluded that in the future functional imaging will provide a valuable adjunct to clinical assessment when judging the efficacy of putative neuroprotective approaches to PD. © 2004 The American Society for Experimental NeuroTherapeutics, Inc.

引用

页码：243 / 254

页数：11

共 94 条

[41]

Snow B., Tooyama I., McGeer E., Et al., Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels, Ann Neurol, 34, pp. 324-330, (1993)

[42]

Pate B., Kawamata T., Yamada T., Et al., Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices, Ann Neurol, 34, pp. 331-338, (1993)

[43]

Rakshi J., Bailey D., Morrish P., Brooks D., Implementation of 3D acquisition, reconstruction, and analysis of dynamic [18F] Fluorodopa studies, Quantification of brain function using PET, pp. 82-87, (1996)

[44]

Ceravolo R., Piccini P., Bailey D., Et al., 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease, Synapse, 43, pp. 201-207, (2002)

[45]

Turjanski N., Lees A., Brooks D., Striatal dopaminergic receptor dysfunction in patients with restless legs syndrome: 18F-dopa and 11C-raclopride PET studies, Neurology, 52, pp. 932-937, (1999)

[46]

Innis R., Marek K., Sheff K., Et al., Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [I-123]β-CIT, Mov Disord, 14, pp. 436-442, (1999)

[47]

Vingerhoets F., Snow B., Lee C., Et al., Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism, Ann Neurol, 36, pp. 759-764, (1994)

[48]

Morrish P., Rakshi J., Sawle G., Brooks D., Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET, J Neurol Neurosurg Psychiatry, 64, pp. 314-319, (1998)

[49]

Nurmi E., Ruottinen H., Bergman J., Et al., Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study, Mov Disord, 16, pp. 608-615, (2001)

[50]

Nurmi E., Ruottinen H., Kaasinen V., Et al., Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand, Ann Neurol, 47, pp. 804-808, (2000)

← 1 2 3 4 5 6 7 8 9 10 →